Baird lowered the firm’s price target on Humana (HUM) to $297 from $300 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana implements measures to expedite approvals
- MA Stars loss for Humana baked into earnings bridge, says Morgan Stanley
- Humana investors assumed low odds of Stars suit success, says Wells Fargo
- Humana loses CMS lawsuit, as expected, says Mizuho
- Humana can refile Stars lawsuit at later date, says Barclays